Expression of AR-V7 and ARv
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Biomarkers, Tumor
/ genetics
Docetaxel
/ pharmacology
Drug Resistance, Neoplasm
/ genetics
Humans
Kallikreins
/ blood
Male
Middle Aged
Neoplastic Cells, Circulating
/ metabolism
Prednisone
/ pharmacology
Progression-Free Survival
Prostate-Specific Antigen
/ blood
Prostatic Neoplasms, Castration-Resistant
/ blood
Protein Isoforms
/ genetics
Receptors, Androgen
/ genetics
Taxoids
/ pharmacology
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 03 2019
15 03 2019
Historique:
received:
26
01
2018
revised:
11
05
2018
accepted:
03
10
2018
pubmed:
12
10
2018
medline:
28
5
2020
entrez:
11
10
2018
Statut:
ppublish
Résumé
Biomarkers aiding treatment optimization in metastatic castration-resistant prostate cancer (mCRPC) are scarce. The presence or absence of androgen receptor (AR) splice variants, AR-V7 and AR Of the 54 evaluable patients, 36 (67%) were AR-V7 Although detection of both CTC-specific AR-V7 and AR
Identifiants
pubmed: 30301829
pii: 1078-0432.CCR-18-0320
doi: 10.1158/1078-0432.CCR-18-0320
pmc: PMC6432911
mid: NIHMS1509272
doi:
Substances chimiques
AR protein, human
0
Biomarkers, Tumor
0
Protein Isoforms
0
Receptors, Androgen
0
Taxoids
0
Docetaxel
15H5577CQD
cabazitaxel
51F690397J
KLK3 protein, human
EC 3.4.21.-
Kallikreins
EC 3.4.21.-
Prostate-Specific Antigen
EC 3.4.21.77
Prednisone
VB0R961HZT
Banques de données
ClinicalTrials.gov
['NCT01718353']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1880-1888Subventions
Organisme : NCI NIH HHS
ID : R21 CA216800
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA062948
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA203702
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
©2018 American Association for Cancer Research.
Références
J Urol. 2016 Dec;196(6):1758-1763
pubmed: 27449259
Thorax. 2008 Feb;63(2):154-9
pubmed: 17693588
Plant Methods. 2014 Dec 31;10(1):42
pubmed: 25628753
PLoS One. 2013 Sep 20;8(9):e75296
pubmed: 24073259
Cancer Res. 2014 Apr 15;74(8):2270-2282
pubmed: 24556717
Cancer Res. 2011 Sep 15;71(18):6019-29
pubmed: 21799031
J Neurovirol. 2014 Aug;20(4):341-51
pubmed: 24781526
Cancer Discov. 2018 Mar;8(3):288-303
pubmed: 29301747
J Clin Oncol. 2017 Jul 1;35(19):2149-2156
pubmed: 28384066
Eur Urol. 2017 Jun;71(6):874-882
pubmed: 27979426
Cancer Res. 2010 Oct 15;70(20):7992-8002
pubmed: 20807808
Clin Cancer Res. 2017 Feb 1;23(3):726-734
pubmed: 27489290
Anal Bioanal Chem. 2014 Oct;406(26):6471-83
pubmed: 24858468
Cancer Treat Rev. 2017 Jun;57:16-27
pubmed: 28527407
Anal Chem. 2012 Jan 17;84(2):1003-11
pubmed: 22122760
Cancer Res. 2009 Jan 1;69(1):16-22
pubmed: 19117982
Sci Rep. 2015 Jan 07;5:7654
pubmed: 25563505
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41
pubmed: 10430926
J Virol Methods. 2013 Dec;194(1-2):229-34
pubmed: 24035807
Prostate. 2015 Nov;75(15):1814-20
pubmed: 26306637
Ann Oncol. 2017 Jul 01;28(7):1508-1516
pubmed: 28472366
PLoS One. 2011 Apr 28;6(4):e19059
pubmed: 21552559
J Clin Oncol. 2017 Oct 1;35(28):3181-3188
pubmed: 28632486
Clin Cancer Res. 2017 Aug 15;23(16):4704-4715
pubmed: 28473535
Eur Urol. 2017 Nov;72(5):828-834
pubmed: 28818355
Oncol Rev. 2016 May 30;10(1):297
pubmed: 27471583
JAMA Oncol. 2016 Nov 01;2(11):1441-1449
pubmed: 27262168
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
J Mol Diagn. 2017 Jan;19(1):115-125
pubmed: 27916435
Nat Commun. 2014 Nov 25;5:5548
pubmed: 25420520
Urology. 2017 Nov;109:6-18
pubmed: 28797685
Int J Mol Sci. 2016 Aug 04;17(8):
pubmed: 27527157
Oncotarget. 2015 Sep 15;6(27):23358-71
pubmed: 26160840
N Engl J Med. 2014 Dec 4;371(23):2234
pubmed: 25470700
Cancer Res. 2008 Jul 1;68(13):5469-77
pubmed: 18593950
Environ Sci Technol. 2015 May 5;49(9):5601-8
pubmed: 25850372
JAMA Oncol. 2015 Aug;1(5):582-91
pubmed: 26181238
Cancer Res. 2012 Sep 15;72(18):4611-5
pubmed: 22987486
Urol Oncol. 2017 Aug;35(8):535
pubmed: 28623072
Oncotarget. 2015 Apr 23;10(41):4213-4223
pubmed: 31289619
PLoS One. 2012;7(4):e35976
pubmed: 22558290
Eur Urol. 2015 Dec;68(6):939-45
pubmed: 26188394